ArticleBMC microbiology2026
Insights into the proteome of next-generation probiotic Faecalibacterium duncaniae A2-165 through label-free proteomics approach.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFaecalibacterium duncaniae A2-165 is a rod-shaped, non-motile, and Extremely Sensitive to Oxygen microorganism, belonging to one of the most abundant genera in the human gut microbiome. A decreased abundance of Faecalibacterium species is correlated with Inflammatory Bowel Diseases (IBDs), highlighting this genus as a marker of gut health and a promising Next-Generation Probiotic. While the anti-inflammatory effects of F. duncaniae A2-165 are well known, current studies lack a global protein-level understanding of this species’ metabolism. To address this issue, this study investigated the proteome of F. duncaniae A2-165 during the stationary phase using a label-free LC-MS/MS proteomics approach.
resultsWe quantified 1,280 proteins in total, corresponding to 44.7% of the in silico predicted proteome, with a clear distinction between insoluble and soluble protein abundances. The subcellular localization predictions for the quantified proteins identified 802 cytoplasmic proteins, 265 membrane proteins, six extracellular proteins, eight cell wall proteins, and 199 proteins with unknown localization. Functional analysis of the differentially abundant proteins between insoluble and soluble fractions showed a predominance of transporter proteins in the insoluble fraction. At the same time, the metabolism of amino acids, carbohydrates, and nucleotides was predominant in the soluble fraction. Further analysis of enriched pathways for each fraction showed that energy metabolism, carbon cycle, and amino acid metabolism were enriched in the soluble fraction. In contrast, ABC transporters, quorum sensing, and oxidative phosphorylation were enriched in the insoluble fraction. We identified proteins associated with anti-inflammatory effects, notably the key butyrate-production protein ButCoAT, the MAM protein and its ABC transporter, and shikimate pathway enzymes.
conclusionThis study characterized, for the first time, the F. duncaniae A2-165 proteome in the stationary phase, profiling the subproteomes of soluble and insoluble fractions and identifying key proteins involved in F. duncaniae A2-165 metabolism at the protein level. The results presented here could provide new insights into the study of F. duncaniae A2-165.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.